Abstract:
Mild cognitive impairment (MCI) is a syndrome characterized as an early stage of
cognitive deterioration greater than that expected of normal aging. It is a complex condition
with a varied etiology which leads to different neurological disorders. There is no specific
diagnostic tool for MCI and its prognosis cannot be determined. Therefore, the
identification of disease biomarkers that can specify the prognosis of the condition as well
as elucidate the pathophysiology is required. The present study investigated the genetic and
molecular markers present in whole blood and plasma samples of MCI subjects. The study
investigated the proxy single nucleotide polymorphisms (SNPs) to assess their role in MCI
disease progression and susceptibility. Six novel proxy SNPs (rs1760252C > A, rs199513T
> C, rs990706G > A, rs1651010A > G, rs2274881A > C, rs10816832C > T) were validated
via sequence specific PCR out of which rs1760252C > A, rs199513T > C and rs10816832C
> T were found to be significantly associated with MCI. The affected genes affected by the
SNPs were evaluated for their biological processes using ShinyGO v.0.76.2 while their
protein-protein interactions were predicted via STRING v.11.5. The association of the
proteins of affected genes elucidates the relationship of the significant SNPs with MCI
pathology. The study also investigated the differential expression and differential
glycosylation of plasma proteins via two-dimensional gel electrophoresis (2DE) and
glycosylation staining as well as analysis of differentially expressed metabolites present in
the plasma samples were identified through gas chromatography mass spectrometry (GC MS). Additionally, western blot analysis was also performed to evaluate the expression of
activating transcription factor 6 (ATF6) in plasma to understand the endoplasmic reticulum
stress (ER) in MCI. Although a slight increase was observed in the expression of ATF6
List of Abbreviations
xix
between MCI and control group but statistically insignificant, however the trend indicates
the presence of ER stress in MCI. The 2DE analysis revealed a total of 8 significant protein
spots to be differentially expressed in MCI as compared to normal subjects. The
metabolomic analysis of plasma samples via GC-MS revealed a total of 72 metabolites.
Further analysis of the screened metabolites through MetaboAnalyst v.5.0, revealed 36
metabolites as statistically different in MCI using Student’s t-test. These significantly
differential metabolites are involved in fatty acid biosynthesis, linoleic acid metabolism,
steroid biosynthesis, primary bile acid biosynthesis and steroid hormone biosynthesis
assessed through Kyoto encyclopedia of genes and genomes (KEGG) Pathway database.
The identified proteomic and metabolomic biomarkers could aid in elaborating our
understanding of the pathophysiology as well as serve as potential diagnostic and
prognostic markers of MCI